Interobserver variation in CD30 immunohistochemistry interpretation; consequences for patient selection for targeted treatment-Reference-Cited by-同舟云学术

Interobserver variation in CD30 immunohistochemistry interpretation; consequences for patient selection for targeted treatment

Author:

Koens Lianne¹^ORCID,van de Ven Peter M²,Hijmering Nathalie J³,Kersten Marie J⁴,Diepstra Arjan⁵,Chamuleau Martine⁶,de Jong Daphne³

Affiliation:

1. Department of Pathology; Academic Medical Center; Amsterdam the Netherlands

2. Department of Epidemiology and Biostatistics; VU Medical Center; Amsterdam the Netherlands

3. Department of Pathology; VU Medical Center; Amsterdam the Netherlands

4. Department of Hematology; Academic Medical Center; Amsterdam the Netherlands

5. Department of Pathology and Medical Biology; University of Groningen; University Medical Center Groningen; Groningen the Netherlands

6. Department of Hematology; VU Medical Center; Amsterdam the Netherlands

Funder

Takeda Netherlands

Publisher

Wiley

Subject

General Medicine,Histology,Pathology and Forensic Medicine

Link

Reference22 articles.

4. CD30-targeted antibody therapy;Younes;Curr. Opin. Oncol.,2011

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

4. QuPath Analysis for CD30+ Cutaneous T-Cell Lymphoma;The American Journal of Dermatopathology;2023-02